- Home
- AADI vs AVTE Comparison
AADI vs AVTE Comparison
Compare AADI & AVTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AADI
- AVTE
- Stock Information
- Founded
- AADI 2011
- AVTE 2018
- Country
- AADI United States
- AVTE United States
- Employees
- AADI N/A
- AVTE N/A
- Industry
- AADI Biotechnology: Pharmaceutical Preparations
- AVTE Biotechnology: Pharmaceutical Preparations
- Sector
- AADI Health Care
- AVTE Health Care
- Exchange
- AADI Nasdaq
- AVTE Nasdaq
- Market Cap
- AADI 77.5M
- AVTE 68.7M
- IPO Year
- AADI N/A
- AVTE 2021
- Fundamental
- Price
- AADI $2.79
- AVTE $2.37
- Analyst Decision
- AADI Hold
- AVTE Hold
- Analyst Count
- AADI 3
- AVTE 7
- Target Price
- AADI $1.75
- AVTE $11.75
- AVG Volume (30 Days)
- AADI 114.1K
- AVTE 140.8K
- Earning Date
- AADI 03-12-2025
- AVTE 03-24-2025
- Dividend Yield
- AADI N/A
- AVTE N/A
- EPS Growth
- AADI N/A
- AVTE N/A
- EPS
- AADI N/A
- AVTE N/A
- Revenue
- AADI $25,070,000.00
- AVTE N/A
- Revenue This Year
- AADI $8.43
- AVTE N/A
- Revenue Next Year
- AADI $5.41
- AVTE N/A
- P/E Ratio
- AADI N/A
- AVTE N/A
- Revenue Growth
- AADI 7.80
- AVTE N/A
- 52 Week Low
- AADI $1.21
- AVTE $1.25
- 52 Week High
- AADI $3.81
- AVTE $32.42
- Technical
- Relative Strength Index (RSI)
- AADI 48.57
- AVTE 37.24
- Support Level
- AADI $2.56
- AVTE $2.35
- Resistance Level
- AADI $2.94
- AVTE $2.49
- Average True Range (ATR)
- AADI 0.13
- AVTE 0.10
- MACD
- AADI 0.01
- AVTE -0.01
- Stochastic Oscillator
- AADI 57.50
- AVTE 11.43
About AADI Aadi Bioscience Inc.
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.
About AVTE Aerovate Therapeutics Inc.
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.